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Drug-target residence time 
A case for the adenosine A1 and A2A receptors 
 
1. The importance of kinetics in drug-target interactions, and particularly the 
residence time of a drug at its target, is increasingly recognized to play a pivotal 
role in determining both the efficacy and toxicity of a drug.  
Zhang,	  R.	  and	  Monsma,	  F.	  Curr	  Opin	  Drug	  Discov	  Devel,	  2009,	  12:488-­‐496	  
 
2. The in vivo duration of drug action not only depends on macroscopic 
pharmacokinetic properties like plasma half-life and the time needed to 
equilibrate between the plasma and the effect compartments, but is also 
influenced by long-lasting target binding and rebinding. 
Vauquelin,	  G.	  and	  Charlton,	  SJ.	  Br	  J	  Pharmacol,	  2010,	  161:488-­‐508.	  
	  
3. Manipulating physicochemical properties such as lipophilicity or molecular 
weight can lead to tuned drug-target residence times. However, these ‘intuitive’, 
‘one size-fits-all’ approaches are very likely too simple and may increase the 
concern of binding to collateral targets, thereby resulting in unwanted side 
effects. 
This	  thesis,	  Chapter	  2	  
	  
4. During the binding and unbinding process tremendous hydration and 
dehydration of both the ligand and the receptor is involved, which appears to be 
a critical process of great generality for a ligand’s association to and egress from 
its receptor. 
Kruse,	  AC.	  et	  al,	  Nature	  2012,	  482:552-­‐556.	  
 
5. A strategy is warranted that comprises both a structure-kinetics relationship 
study (SKR) and a classical structure-affinity relationship study (SAR). This 
may offer added value to the traditional metrics of affinity-based drug 
evaluation. 
This	  thesis,	  Chapter	  2	  and	  Chapter	  4	  
  
6. Kinetic models incorporating the mean lifetime of specific complexes will be 
required to fully explain the nature of agonist efficacy. 
Sykes	  DA	  et	  al.	  Mol	  Pharmacol,	  2009,	  76:543-­‐551;	  this	  thesis,	  Chapter	  5	  
	  
7. The strength of mathematical simulations is not restricted to validating 
experimental data. It also facilitates our understanding of complicated ligand-
receptor interactions especially for those experimental observations otherwise 
difficult to interpret. 
This	  thesis,	  Chapter	  6	  and	  Chapter	  7	  
 
8. The value of binding kinetics to drug discovery will be increased through an 
improved ability to identify optimal kinetic mechanisms and define kinetic 
structure activity relationships. 
Swinney DC, Curr Opin Drug Discov Devel. 2009, 12:31-39. 
 
9. “Unknown unknowns; known unknowns; unknown knowns; known knowns” 
pretty much sketches the four statuses of a PhD student. 
 
10. Punctuality is a good virtue—particularly for one who studies binding 
kinetics. 
 
11. Proper chemistry and decent cooking are alike. The only difference is that 
when it starts to smell, the former works, while the latter does not. 
 
12. “…Just play. Have fun. Enjoy the game.” 
Michael Jordan 
 
 
 
 
 
